SCHEMBL29831708

SCHEMBL29831708

CCOC(=O)c1sc(Nc2nc(-c3cc(OC)c(OC)c(OC)c3)cc(N3CCC(O)CC3)n2)nc1C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 6/20 0.75
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 4/20 0.52
MAPT P10636 4/20 0.52
LMNA P02545 3/20 0.49
HPGD P15428 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PDE2A O00408 1/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
DHODH Q02127 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL291384 1.00 PDE5A (0.75) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL291444 0.90 PDE5A (0.74) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL27937619 0.90 PDE5A (0.59) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL2680304 0.90 PDE5A (0.62) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL291321 0.86 PDE5A (0.76) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL290844 0.86 PDE5A (1.00) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL291110 0.86 PDE5A (0.79) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL29831789 0.86 PDE5A (0.79) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL6068543 0.86 PDE5A (0.79) PDE5AALDH1A1KDM4EMAPTLMNA
SCHEMBL28562458 0.86 PDE5A (0.71) PDE5AALDH1A1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed
EP-4275752-A2 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS Omeros Corporation (US) 2023-11-15 EP disclosed
CN-115192711-A Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2022-10-18 CN disclosed
CN-114984229-A Treatment of addiction and impulse control disorders using PDE7 inhibitors 奥默罗斯公司 2022-09-02 CN disclosed